Integrated analysis identifies interaction patterns between small molecules and pathways

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Li, Yan ^a   Li, Weiguo ^a   Chen, Xin ^b   Jiang, Hong ^a   Sun, Jiatong ^a   Chen, Huan ^a   Lv, Sali ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b University of Macau   (Macao)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ADIPHENINE; ALVESPIMYCIN; AMIODARONE; BIPERIDEN; LEVODOPA; LISURIDE; MONENSIN; RADICICOL; TANESPIMYCIN; VORINOSTAT; TRANSCRIPTOME;

ARTICLE; BREAST CANCER; CANCER CELL LINE; GAP JUNCTION; GENE EXPRESSION; LIVER CANCER; LUNG CANCER; MOLECULARLY TARGETED THERAPY; MOLECULE; PROTEIN ANALYSIS; PROTEIN INTERACTION; PROTEIN LOCALIZATION; BIOLOGY; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETICS; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGY; PROCEDURES; SIGNAL TRANSDUCTION;

CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; TRANSCRIPTOME;

EID: 84927794932     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/931825     Document Type: Article

References (46)

1. A. M. Gonzalez-Angulo, G. N. Hortobágyi, and F. J. Esteva, "Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer, " Oncologist, vol. 11, no. 8, pp. 857-867, 2006.
2. J. Tabernero, "The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR Agents, " Molecular Cancer Research, vol. 5, no. 3, pp. 203-220, 2007.
3. T. J. Hobday and E. A. Perez, "Molecularly targeted therapies for breast cancer, " Cancer Control, vol. 12, no. 2, pp. 73-81, 2005.
4. F. G. Kuruvilla, A. F. Shamji, S. M. Sternson, P. J. Hergenrother, and S. L. Schreiber, "Dissecting glucose signalling with diversity-oriented synthesis and small-molecule microarrays, " Nature, vol. 416, no. 6881, pp. 653-657, 2002.
5. R. A. Pache, A. Zanzoni, J. Naval, J. M. Mas, and P. Aloy, "Towards a molecular characterisation of pathological pathways, " The FEBS Letters, vol. 582, no. 8, pp. 1259-1265, 2008.
6. C. F. Thorn, M. Whirl-Carrillo, T. E. Klein, and R. B. Altman, "Pathway-based approaches to pharmacogenomics, " Current Pharmacogenomics, vol. 5, no. 1, pp. 79-86, 2007.
7. D. C. Altieri, "Survivin, cancer networks and pathway-directed drug discovery, " Nature Reviews Cancer, vol. 8, no. 1, pp. 61-70, 2008.
8. M. K. Hellerstein, "Acritique of themolecular target-based drug discovery paradigm based on principles of metabolic control: advantages of pathway-based discovery, "Metabolic Engineering, vol. 10, no. 1, pp. 1-9, 2008.
9. D. R. Rhodes, S. Kalyana-Sundaram, S. A. Tomlins, et al., "Molecular concepts analysis links tumors, pathways, mechanisms, and drugs, " Neoplasia, vol. 9, no. 5, pp. 443-454, 2007.
10. S. Chian, R. Thapa, Z. Chi, X. J. Wang, and X. Tang, "Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo, " Biochemical and Biophysical Research Communications, vol. 447, no. 4, pp. 602-608, 2014.
11. C. Gallo-Ebert, M. Donigan, I. L. Stroke, et al., "Novel antifungal drug discovery based on targeting pathways regulating the fungus-conserved Upc2 transcription factor, " Antimicrobial Agents and Chemotherapy, vol. 58, no. 1, pp. 258-266, 2014.
12. S. M. An, Q. P. Ding, and L. S. Li, "Stem cell signaling as a target for novel drug discovery: recent progress in theWNTand Hedgehog pathways, " Acta Pharmacologica Sinica, vol. 34, no. 6, pp. 777-783, 2013.
13. S. Huber, S. Valente, P. Chaimbault, and H. Schohn, "Evaluation of δ2-pioglitazone, an analogue of pioglitazone, on colon cancer cell survival: evidence of drug treatment association with autophagy and activation of the Nrf2/Keap1 pathway, " International Journal of Oncology, vol. 45, no. 1, pp. 426-438, 2014.
14. R. C. Arend, A. I. Londono-Joshi, R. S. Samant, et al., "Inhibition of Wnt/beta-catenin pathway by niclosamide: a therapeutic target for ovarian cancer, " Gynecologic Oncology, vol. 134, no. 1, pp. 112-120, 2014.
15. C. Garcia-Echeverria and W. R. Sellers, "Drug discovery approaches targeting the PI3K/Akt pathway in cancer, " Oncogene, vol. 27, no. 41, pp. 5511-5526, 2008.
16. I. Collins and P. Workman, "New approaches to molecular cancer therapeutics, " Nature Chemical Biology, vol. 2, no. 12, pp. 689-700, 2006.
17. A. W. E. Chan and M. P. Weir, "Using chemistry to target treatments, " Chemical Innovation, vol. 31, no. 12, pp. 12-17, 2001.
18. J. Lamb, E. D. Crawford, D. Peck, et al., "The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease, " Science, vol. 313, no. 5795, pp. 1929-1935, 2006.
19. J. Lamb, "The Connectivity Map: a new tool for biomedical research, " Nature Reviews Cancer, vol. 7, no. 1, pp. 54-60, 2007.
20. D. S. Wishart, C. Knox, A. C. Guo, et al., "DrugBank: a comprehensive resource for in silico drug discovery and exploration, " Nucleic Acids Research, vol. 34, pp. D668-D672, 2006.
21. D. S. Wishart, C. Knox, A. C. Guo, et al., "DrugBank: a knowledgebase for drugs, drug actions and drug targets, " Nucleic Acids Research, vol. 36, pp. D901-D906, 2008.
22. A. P. Davis, C. G. Murphy, C. A. Saraceni-Richards, M. C. Rosenstein, T. C. Wiegers, and C. J. Mattingly, "Comparative toxicogenomics database: a knowledgebase and discovery tool for chemical-gene-disease networks, " Nucleic Acids Research, vol. 37, no. 1, pp. D786-D792, 2009.
23. J. Wixon and D. Kell, "The Kyoto encyclopedia of genes and genomes-KEGG, " Yeast, vol. 17, no. 1, pp. 48-55, 2000.
24. E. W. Sayers, "Database resources of the National Center for Biotechnology Information, " Nucleic Acids Research, vol. 37, supplement 1, pp. D5-D15, 2009.
25. A. J. Butte, J. Ye, H. U. Häring, M. Stumvoll, M. F. White, and I. S. Kohane, "Determining significant fold differences in gene expression analysis, " Pacific Symposiumon Biocomputing, pp. 6-17, 2001.
26. V. G. Tusher, R. Tibshirani, and G. Chu, "Significance analysis of microarrays applied to the ionizing radiation response, " Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 9, pp. 5116-5121, 2001.
27. B. Zhang, S. Kirov, and J. Snoddy, "WebGestalt: an integrated system for exploring gene sets in various biological contexts, " Nucleic Acids Research, vol. 33, no. 2, pp. W741-W748, 2005.
28. I. Rivals, L. Personnaz, L. Taing, and M. Potier, "Enrichment or depletion of a GO category within a class of genes: which test?" Bioinformatics, vol. 23, no. 4, pp. 401-407, 2007.
29. M. R. Green, "Targeting targeted therapy, " The New England Journal of Medicine, vol. 350, no. 21, pp. 2191-2193, 2004.
30. F. Chang, J. T. Lee, P. M. Navolanic, et al., "Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy, " Leukemia, vol. 17, no. 3, pp. 590-603, 2003.
31. C. Blancher, J. W. Moore, N. Robertson, and A. L. Harris, "Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1, HIF-2, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3-kinase/Akt signaling pathway, " Cancer Research, vol. 61, no. 19, pp. 7349-7355, 2001.
32. T. Lahusen, A. de Siervi, C. Kunick, and A. M. Senderowicz, "Alsterpaullone, a novel cyclin-dependent kinase inhibitor, induces apoptosis by activation of caspase-9 due to perturbation in mitochondrial membrane potential, " Molecular Carcinogenesis, vol. 36, no. 4, pp. 183-194, 2003.
33. L. Meijer, M. Flajolet, and P. Greengard, "Pharmacological inhibitors of glycogen synthase kinase 3, " Trends in Pharmacological Sciences, vol. 25, no. 9, pp. 471-480, 2004.
34. E. ter Haar, J. T. Coll, D. A. Austen, H. M. Hsiao, L. Swenson, and J. Jain, "Structure of GSK3beta reveals a primed phosphorylation mechanism, " Nature Structural Biology, vol. 8, no. 7, pp. 593-596, 2001.
35. Y. Li, P. Hao, S. Zheng, et al., "Gene expression module-based chemical function similarity search, " Nucleic Acids Research, vol. 36, no. 20, article e137, 2008.
36. C. Bokemeyer, C. Kollmannsberger, S. Stenning, et al., "Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials, " The British Journal of Cancer, vol. 91, no. 4, pp. 683-687, 2004.
37. Y. Liu, B. Hu, C. Fu, and X. Chen, "DCDB: drug combination database, " Bioinformatics, vol. 26, no. 4, pp. 587-588, 2010.
38. J. Jiang, P. Nilsson-Ehle, and N. Xu, "Influence of liver cancer on lipid and lipoproteinmetabolism, " Lipids in Health and Disease, vol. 5, article 4, 2006.
39. J. T. Jiang, C. Wu, N. Xu, and X. Zhang, "Mechanisms and significance of lipoprotein(a) in hepatocellular carcinoma, " Hepatobiliary and Pancreatic Diseases International, vol. 8, no. 1, pp. 25-28, 2009.
40. X. Liang, A. R. Chavez, N. E. Schapiro, et al., "Ethyl pyruvate administration inhibits hepatic tumor growth, " Journal of Leukocyte Biology, vol. 86, no. 3, pp. 599-607, 2009.
41. H. S. Seo, D. G. DeNardo, Y. Jacquot, et al., "Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha, " Breast Cancer Research and Treatment, vol. 99, no. 2, pp. 121-134, 2006.
42. S. Cheng, N. Gao, Z. Zhang, et al., "Quercetin induces tumorselective apoptosis through downregulation of Mcl-1 and activation of bax, " Clinical Cancer Research, vol. 16, no. 23, pp. 5679-5691, 2010.
43. S. T. Philips, Z. L. Hildenbrand, K. I. Oravecz-Wilson, S. B. Foley, V. E. Mgbemena, and T. S. Ross, "Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasminitiating cells, " Oncogene, 2013.
44. M. A. Scheper, N. G. Nikitakis, R. Chaisuparat, S. Montaner, and J. J. Sauk, "Sulindac induces apoptosis and inhibits tumor growth in vivo in head and neck squamous cell carcinoma, " Neoplasia, vol. 9, no. 3, pp. 192-199, 2007.
45. M. R. Ramsey, L. He, N. Forster, B. Ory, and L. W. Ellisen, "Physical association ofHDAC1 andHDAC2 with p63mediates transcriptional repression and tumormaintenance in squamous cell carcinoma, " Cancer Research, vol. 71, no. 13, pp. 4373-4379, 2011.
46. M. Zhang, L. Zhang, J. Zou, et al., "Evaluating reproducibility of differential expression discoveries in microarray studies by considering correlated molecular changes, " Bioinformatics, vol. 25, no. 13, pp. 1662-1668, 2009.